UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 42

Sortiert nach

5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e15540-e15540

2018

Link zum Volltext

Verfügbarkeit prüfen

521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A9-A9

2024

Link zum Volltext

Verfügbarkeit prüfen

638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A730-A730

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract A118: PIKHER2: A phase Ib study evaluating oral BKM120 in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.A118-A118

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P02-P02-01

2021

Link zum Volltext

Verfügbarkeit prüfen

Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.11556-11556

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2005-2005

2023

Link zum Volltext

Verfügbarkeit prüfen

Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection

Kidney international, 2017-07, Vol.92 (1), p.214-226

2017

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: ESMO Open 3 (2018) e000375

ESMO open, 2023-03, Vol.8 (2)

2023

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: [ESMO Open 3 (2018) e000375]

ESMO open, 2023-04, Vol.8 (2), p.101185-101185, Article 101185

2023

Link zum Volltext

Verfügbarkeit prüfen

ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study

Neuroendocrinology, 2021-09, Vol.111 (10), p.951-964

2021

Link zum Volltext

Verfügbarkeit prüfen

CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii63-vii63

2022

Link zum Volltext

Verfügbarkeit prüfen

CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v67-v68

2023

Link zum Volltext

Verfügbarkeit prüfen

Dacarbazine mediate antimelanoma effects via NK cells

Oncoimmunology, 2013-04, Vol.2 (4), p.e23714-e23714

2013

Link zum Volltext

Verfügbarkeit prüfen

Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth

Journal of investigative dermatology, 2013-02, Vol.133 (2), p.499-508

2013

Link zum Volltext

Verfügbarkeit prüfen

Dacarbazine mediates antimelanoma effects via NK cells

Oncoimmunology, 2013-04, Vol.2 (4), p.e23714

2013

Link zum Volltext

Verfügbarkeit prüfen

EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2020-2020

2023

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

European journal of cancer (1990), 2017-12, Vol.87, p.131-139

2017

Link zum Volltext

Verfügbarkeit prüfen

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study

Oncoimmunology, 2018-09, Vol.7 (9), p.e1474319-e1474319

2018

Link zum Volltext

Verfügbarkeit prüfen

Implementation and use of whole exome sequencing for metastatic solid cancer

EBioMedicine, 2020-01, Vol.51, p.102624-102624, Article 102624

2020

Link zum Volltext

Verfügbarkeit prüfen

Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?

Cancers, 2021-08, Vol.13 (16), p.4152

2021

Link zum Volltext

Verfügbarkeit prüfen

Limbs and trunk soft tissue sarcoma systematic local and remote monitoring by MRI and thoraco-abdomino-pelvic scanner: A single-centre retrospective study

European journal of surgical oncology, 2019-07, Vol.45 (7), p.1274-1280

2019

Link zum Volltext

Verfügbarkeit prüfen

Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e14071-e14071

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 42

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

5-fluorouracil plus bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): An investigator-initiated, open-label, single-arm, multicentre, phase 2 study

521 Safety and efficacy of Durvalumab (D) + Tremelimumab (T) + Metronomic Oral Vinorelbine (MOV) in patients with recurrent/metastatic cervical cancer (RMCC) in the MOVIE trial

638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Abstract A118: PIKHER2: A phase Ib study evaluating oral BKM120 in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer

Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial

Activity of cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma: European Organization for Research and Treatment of Cancer (EORTC) Phase II trial 1202

Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study

Computer-assisted topological analysis of renal allograft inflammation adds to risk evaluation at diagnosis of humoral rejection

Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: ESMO Open 3 (2018) e000375

Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer”: [ESMO Open 3 (2018) e000375]

ctDNA in Neuroendocrine Carcinoma of Gastroenteropancreatic Origin or of Unknown Primary: The CIRCAN-NEC Pilot Study

CTIM-17. EO2401 THERAPEUTIC VACCINE FOR PATIENTS WITH RECURRENT GLIOBLASTOMA: PHASE 1/2 ROSALIE STUDY (NCT04116658)

CTIM-25. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: THE PHASE 1/2 EOGBM1-18/ROSALIE STUDY (NCT04116658)

Dacarbazine mediate antimelanoma effects via NK cells

Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth

Dacarbazine mediates antimelanoma effects via NK cells

Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study

EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study

Impact of the Covid‐19 pandemic on melanoma diagnosis: A retrospective study from the French clinical database of melanoma patients (RIC‐Mel)

Implementation and use of whole exome sequencing for metastatic solid cancer

Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?

Limbs and trunk soft tissue sarcoma systematic local and remote monitoring by MRI and thoraco-abdomino-pelvic scanner: A single-centre retrospective study

Machine learning models to predict the response to anti-cancer therapy in metastatic melanoma patients

Suchergebnisse filtern